Analyze Diet
Molecular and cellular biology2000; 20(10); 3550-3557; doi: 10.1128/MCB.20.10.3550-3557.2000

Binding of equine infectious anemia virus rev to an exon splicing enhancer mediates alternative splicing and nuclear export of viral mRNAs.

Abstract: In addition to facilitating the nuclear export of incompletely spliced viral mRNAs, equine infectious anemia virus (EIAV) Rev regulates alternative splicing of the third exon of the tat/rev mRNA. In the presence of Rev, this exon of the bicistronic RNA is skipped in a fraction of the spliced mRNAs. In this report, the cis-acting requirements for exon 3 usage were correlated with sequences necessary for Rev binding and transport of incompletely spliced RNA. The presence of a purine-rich exon splicing enhancer (ESE) was required for exon 3 recognition, and the addition of Rev inhibited exon 3 splicing. Glutathione-S-transferase (GST)-Rev bound to probes containing the ESE, and mutation of GAA repeats to GCA within the ESE inhibited both exon 3 recognition in RNA splicing experiments and GST-Rev binding in vitro. These results suggest that Rev regulates alternative splicing by binding at or near the ESE to block SR protein-ESE interactions. A 57-nucleotide sequence containing the ESE was sufficient to mediate Rev-dependent nuclear export of incompletely spliced RNAs. Rev export activity was significantly inhibited by mutation of the ESE or by trans-complementation with SF2/ASF. These results indicate that the ESE functions as a Rev-responsive element and demonstrate that EIAV Rev mediates exon 3 exclusion through protein-RNA interactions required for efficient export of incompletely spliced viral RNAs.
Publication Date: 2000-04-25 PubMed ID: 10779344PubMed Central: PMC85647DOI: 10.1128/MCB.20.10.3550-3557.2000Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Journal Article
  • Research Support
  • Non-U.S. Gov't
  • Research Support
  • U.S. Gov't
  • Non-P.H.S.
  • Research Support
  • U.S. Gov't
  • P.H.S.

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research article explores how equine infectious anemia virus (EIAV) Rev protein influences the splicing and nuclear export of viral mRNAs. The findings reveal that the Rev protein binds to a specific sequence in the RNA to regulate alternative splicing and enables the effective exit of incomplete viral RNA from the cell nucleus.

Understanding Rev’s Role in EIAV

  • The equine infectious anemia virus (EIAV) Rev protein does more than just facilitate the nuclear export of incompletely spliced viral mRNAs. It also regulates the splicing of the third exon in the tat/rev mRNA—part of the instructions for producing viral proteins.
  • When the Rev protein is present, some spliced mRNAs skip this third exon in the bicistronic RNA, a type of RNA that can be read in two different ways to produce different products.
  • The researchers correlated the requirements for using this third exon with the necessary sequences for the binding of Rev and the transportation of incomplete RNA.

Functions of the Exon Splicing Enhancer

  • The presence of a purine-rich exon splicing enhancer (ESE), a sequence that promotes the recognition of an exon during the splicing process, is required for the third exon’s recognition.
  • When Rev was added, the researchers found that it inhibited the splicing of this exon. They observed that under certain conditions, the Glutathione-S-transferase (GST)-Rev protein bound to probes that contained this ESE.
  • Experiments revealed that changes to the sequence of this ESE, specifically from GAA repeats to GCA, barred both the recognition of the third exon in RNA splicing experiments and binding to the GST-Rev protein.

Rev’s Mediating Activity and the ESE

  • These results led the researchers to posit that Rev might regulate alternative splicing by binding at or near the ESE, hence blocking the interaction between other proteins and the ESE.
  • A 57-nucleotide long sequence containing the ESE was found to adequately mediate the export of incomplete RNAs from the nucleus depending on the presence of Rev.
  • They discovered that mutations in the ESE or adding in an additional external protein (SF2/ASF) in trans-complementation significantly impaired the function of the Rev protein in exporting RNA.

Implications of Findings

  • The ESE’s functions indicate that it acts as a responsive element to Rev, indicating a crucial role in the virus’s mechanism.
  • The EIAV Rev protein manipulates exon 3 exclusion via protein-RNA interactions which are needed for the efficient exportation of incompletely spliced viral RNAs.
  • This information could be significant in devising treatments for diseases caused by the EIAV, as disrupting this interaction might affect the virus’s ability to replicate.

Cite This Article

APA
Belshan M, Park GS, Bilodeau P, Stoltzfus CM, Carpenter S. (2000). Binding of equine infectious anemia virus rev to an exon splicing enhancer mediates alternative splicing and nuclear export of viral mRNAs. Mol Cell Biol, 20(10), 3550-3557. https://doi.org/10.1128/MCB.20.10.3550-3557.2000

Publication

ISSN: 0270-7306
NlmUniqueID: 8109087
Country: United States
Language: English
Volume: 20
Issue: 10
Pages: 3550-3557

Researcher Affiliations

Belshan, M
  • Department of Veterinary Microbiology and Preventive Medicine, Iowa State University, Ames, Iowa 50011, USA.
Park, G S
    Bilodeau, P
      Stoltzfus, C M
        Carpenter, S

          MeSH Terms

          • Alternative Splicing
          • Binding Sites
          • Biological Transport
          • Cell Nucleus
          • Exons / genetics
          • Gene Products, rev / genetics
          • Gene Products, rev / metabolism
          • Infectious Anemia Virus, Equine / genetics
          • Mutagenesis
          • Nuclear Proteins / metabolism
          • Protein Binding
          • RNA, Messenger / genetics
          • RNA, Messenger / metabolism
          • RNA, Viral / genetics
          • RNA, Viral / metabolism
          • RNA-Binding Proteins
          • Serine-Arginine Splicing Factors

          Grant Funding

          • R01 AI036073 / NIAID NIH HHS
          • R56 AI036073 / NIAID NIH HHS
          • AI36073 / NIAID NIH HHS
          • CA 28951 / NCI NIH HHS

          References

          This article includes 35 references
          1. Ali SA, Steinkasserer A. PCR-ligation-PCR mutagenesis: a protocol for creating gene fusions and mutations.. Biotechniques 1995 May;18(5):746-50.
            pubmed: 7619468
          2. Amendt BA, Hesslein D, Chang LJ, Stoltzfus CM. Presence of negative and positive cis-acting RNA splicing elements within and flanking the first tat coding exon of human immunodeficiency virus type 1.. Mol Cell Biol 1994 Jun;14(6):3960-70.
          3. Beisel CE, Edwards JF, Dunn LL, Rice NR. Analysis of multiple mRNAs from pathogenic equine infectious anemia virus (EIAV) in an acutely infected horse reveals a novel protein, Ttm, derived from the carboxy terminus of the EIAV transmembrane protein.. J Virol 1993 Feb;67(2):832-42.
            pmc: PMC237437pubmed: 8419648doi: 10.1128/JVI.67.2.832-842.1993google scholar: lookup
          4. Belshan M, Harris ME, Shoemaker AE, Hope TJ, Carpenter S. Biological characterization of Rev variation in equine infectious anemia virus.. J Virol 1998 May;72(5):4421-6.
          5. Carpenter S, Alexandersen S, Long MJ, Perryman S, Chesebro B. Identification of a hypervariable region in the long terminal repeat of equine infectious anemia virus.. J Virol 1991 Mar;65(3):1605-10.
          6. Carroll R, Derse D. Translation of equine infectious anemia virus bicistronic tat-rev mRNA requires leaky ribosome scanning of the tat CTG initiation codon.. J Virol 1993 Mar;67(3):1433-40.
          7. Cochrane AW, Chen CH, Rosen CA. Specific interaction of the human immunodeficiency virus Rev protein with a structured region in the env mRNA.. Proc Natl Acad Sci U S A 1990 Feb;87(3):1198-202.
            pmc: PMC53438pubmed: 2405396doi: 10.1073/pnas.87.3.1198google scholar: lookup
          8. Cook KS, Fisk GJ, Hauber J, Usman N, Daly TJ, Rusche JR. Characterization of HIV-1 REV protein: binding stoichiometry and minimal RNA substrate.. Nucleic Acids Res 1991 Apr 11;19(7):1577-83.
            pmc: PMC333918pubmed: 2027765doi: 10.1093/nar/19.7.1577google scholar: lookup
          9. Cullen BR. Mechanism of action of regulatory proteins encoded by complex retroviruses.. Microbiol Rev 1992 Sep;56(3):375-94.
            pmc: PMC372876pubmed: 1406488doi: 10.1128/mr.56.3.375-394.1992google scholar: lookup
          10. Daly TJ, Doten RC, Rennert P, Auer M, Jaksche H, Donner A, Fisk G, Rusche JR. Biochemical characterization of binding of multiple HIV-1 Rev monomeric proteins to the Rev responsive element.. Biochemistry 1993 Oct 5;32(39):10497-505.
            pubmed: 8399195doi: 10.1021/bi00090a028google scholar: lookup
          11. Dayton ET, Konings DA, Powell DM, Shapiro BA, Butini L, Maizel JV, Dayton AI. Extensive sequence-specific information throughout the CAR/RRE, the target sequence of the human immunodeficiency virus type 1 Rev protein.. J Virol 1992 Feb;66(2):1139-51.
          12. Dignam JD, Lebovitz RM, Roeder RG. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei.. Nucleic Acids Res 1983 Mar 11;11(5):1475-89.
            pmc: PMC325809pubmed: 6828386doi: 10.1093/nar/11.5.1475google scholar: lookup
          13. Fischer U, Huber J, Boelens WC, Mattaj IW, Lührmann R. The HIV-1 Rev activation domain is a nuclear export signal that accesses an export pathway used by specific cellular RNAs.. Cell 1995 Aug 11;82(3):475-83.
            pubmed: 7543368doi: 10.1016/0092-8674(95)90436-0google scholar: lookup
          14. Fridell RA, Bogerd HP, Cullen BR. Nuclear export of late HIV-1 mRNAs occurs via a cellular protein export pathway.. Proc Natl Acad Sci U S A 1996 Apr 30;93(9):4421-4.
            pmc: PMC39553pubmed: 8633082doi: 10.1073/pnas.93.9.4421google scholar: lookup
          15. Fridell RA, Partin KM, Carpenter S, Cullen BR. Identification of the activation domain of equine infectious anemia virus rev.. J Virol 1993 Dec;67(12):7317-23.
          16. Fu XD. The superfamily of arginine/serine-rich splicing factors.. RNA 1995 Sep;1(7):663-80.
            pmc: PMC1369309pubmed: 7585252
          17. Gontarek RR, Derse D. Interactions among SR proteins, an exonic splicing enhancer, and a lentivirus Rev protein regulate alternative splicing.. Mol Cell Biol 1996 May;16(5):2325-31.
            pmc: PMC231220pubmed: 8628299doi: 10.1128/MCB.16.5.2325google scholar: lookup
          18. Harris ME, Gontarek RR, Derse D, Hope TJ. Differential requirements for alternative splicing and nuclear export functions of equine infectious anemia virus Rev protein.. Mol Cell Biol 1998 Jul;18(7):3889-99.
            pmc: PMC108973pubmed: 9632773doi: 10.1128/MCB.18.7.3889google scholar: lookup
          19. Jacks T, Madhani HD, Masiarz FR, Varmus HE. Signals for ribosomal frameshifting in the Rous sarcoma virus gag-pol region.. Cell 1988 Nov 4;55(3):447-58.
            pmc: PMC7133365pubmed: 2846182doi: 10.1016/0092-8674(88)90031-1google scholar: lookup
          20. Kawakami T, Sherman L, Dahlberg J, Gazit A, Yaniv A, Tronick SR, Aaronson SA. Nucleotide sequence analysis of equine infectious anemia virus proviral DNA.. Virology 1987 Jun;158(2):300-12.
            pubmed: 3035786doi: 10.1016/0042-6822(87)90202-9google scholar: lookup
          21. Krainer AR, Mayeda A, Kozak D, Binns G. Functional expression of cloned human splicing factor SF2: homology to RNA-binding proteins, U1 70K, and Drosophila splicing regulators.. Cell 1991 Jul 26;66(2):383-94.
            pubmed: 1830244doi: 10.1016/0092-8674(91)90627-bgoogle scholar: lookup
          22. Martarano L, Stephens R, Rice N, Derse D. Equine infectious anemia virus trans-regulatory protein Rev controls viral mRNA stability, accumulation, and alternative splicing.. J Virol 1994 May;68(5):3102-11.
          23. Mayeda A, Screaton GR, Chandler SD, Fu XD, Krainer AR. Substrate specificities of SR proteins in constitutive splicing are determined by their RNA recognition motifs and composite pre-mRNA exonic elements.. Mol Cell Biol 1999 Mar;19(3):1853-63.
            pmc: PMC83978pubmed: 10022872doi: 10.1128/MCB.19.3.1853google scholar: lookup
          24. Olsen HS, Cochrane AW, Dillon PJ, Nalin CM, Rosen CA. Interaction of the human immunodeficiency virus type 1 Rev protein with a structured region in env mRNA is dependent on multimer formation mediated through a basic stretch of amino acids.. Genes Dev 1990 Aug;4(8):1357-64.
            pubmed: 2227413doi: 10.1101/gad.4.8.1357google scholar: lookup
          25. Olsen HS, Nelbock P, Cochrane AW, Rosen CA. Secondary structure is the major determinant for interaction of HIV rev protein with RNA.. Science 1990 Feb 16;247(4944):845-8.
            pubmed: 2406903doi: 10.1126/science.2406903google scholar: lookup
          26. Olsen HS, Beidas S, Dillon P, Rosen CA, Cochrane AW. Mutational analysis of the HIV-1 Rev protein and its target sequence, the Rev responsive element.. J Acquir Immune Defic Syndr (1988) 1991;4(6):558-67.
            pubmed: 2023097
          27. Powell DM, Zhang MJ, Konings DA, Wingfield PT, Stahl SJ, Dayton ET, Dayton AI. Sequence specificity in the higher-order interaction of the Rev protein of HIV-1 with its target sequence, the RRE.. J Acquir Immune Defic Syndr Hum Retrovirol 1995 Nov 1;10(3):317-23.
            pubmed: 7552493
          28. Powell DM, Amaral MC, Wu JY, Maniatis T, Greene WC. HIV Rev-dependent binding of SF2/ASF to the Rev response element: possible role in Rev-mediated inhibition of HIV RNA splicing.. Proc Natl Acad Sci U S A 1997 Feb 4;94(3):973-8.
            pmc: PMC19624pubmed: 9023367doi: 10.1073/pnas.94.3.973google scholar: lookup
          29. Schwartz S, Felber BK, Benko DM, Fenyö EM, Pavlakis GN. Cloning and functional analysis of multiply spliced mRNA species of human immunodeficiency virus type 1.. J Virol 1990 Jun;64(6):2519-29.
          30. Screaton GR, Cáceres JF, Mayeda A, Bell MV, Plebanski M, Jackson DG, Bell JI, Krainer AR. Identification and characterization of three members of the human SR family of pre-mRNA splicing factors.. EMBO J 1995 Sep 1;14(17):4336-49.
          31. Smith TA, Davis E, Carpenter S. Endotoxin treatment of equine infectious anaemia virus-infected horse macrophage cultures decreases production of infectious virus.. J Gen Virol 1998 Apr;79 ( Pt 4):747-55.
            pubmed: 9568970doi: 10.1099/0022-1317-79-4-747google scholar: lookup
          32. Van Ryk DI, Venkatesan S. Real-time kinetics of HIV-1 Rev-Rev response element interactions. Definition of minimal binding sites on RNA and protein and stoichiometric analysis.. J Biol Chem 1999 Jun 18;274(25):17452-63.
            pubmed: 10364175doi: 10.1074/jbc.274.25.17452google scholar: lookup
          33. Zahler AM, Neugebauer KM, Lane WS, Roth MB. Distinct functions of SR proteins in alternative pre-mRNA splicing.. Science 1993 Apr 9;260(5105):219-22.
            pubmed: 8385799doi: 10.1126/science.8385799google scholar: lookup
          34. Zapp ML, Hope TJ, Parslow TG, Green MR. Oligomerization and RNA binding domains of the type 1 human immunodeficiency virus Rev protein: a dual function for an arginine-rich binding motif.. Proc Natl Acad Sci U S A 1991 Sep 1;88(17):7734-8.
            pmc: PMC52377pubmed: 1715576doi: 10.1073/pnas.88.17.7734google scholar: lookup
          35. Zapp ML, Green MR. Sequence-specific RNA binding by the HIV-1 Rev protein.. Nature 1989 Dec 7;342(6250):714-6.
            pubmed: 2556643doi: 10.1038/342714a0google scholar: lookup

          Citations

          This article has been cited 15 times.
          1. Li J, Zhang X, Bai B, Zhang M, Ma W, Lin Y, Wang X, Wang XF. Identification of a Novel Post-transcriptional Transactivator from the Equine Infectious Anemia Virus.. J Virol 2022 Dec 21;96(24):e0121022.
            doi: 10.1128/jvi.01210-22pubmed: 36448796google scholar: lookup
          2. Zhang X, Li J, Zhang M, Bai B, Ma W, Lin Y, Guo X, Wang XF, Wang X. A Novel, Fully Spliced, Accessory Gene in Equine Lentivirus with Distinct Rev-Responsive Element.. J Virol 2022 Sep 28;96(18):e0098622.
            doi: 10.1128/jvi.00986-22pubmed: 36069548google scholar: lookup
          3. O'Carroll IP, Fan L, Kroupa T, McShane EK, Theodore C, Yates EA, Kondrup B, Ding J, Martin TS, Rein A, Wang YX. Structural Mimicry Drives HIV-1 Rev-Mediated HERV-K Expression.. J Mol Biol 2020 Dec 4;432(24):166711.
            doi: 10.1016/j.jmb.2020.11.010pubmed: 33197463google scholar: lookup
          4. Umunnakwe CN, Loyd H, Cornick K, Chavez JR, Dobbs D, Carpenter S. Computational modeling suggests dimerization of equine infectious anemia virus Rev is required for RNA binding.. Retrovirology 2014 Dec 23;11:115.
            doi: 10.1186/s12977-014-0115-7pubmed: 25533001google scholar: lookup
          5. Farley DC, Bannister R, Leroux-Carlucci MA, Evans NE, Miskin JE, Mitrophanous KA. Development of an equine-tropic replication-competent lentivirus assay for equine infectious anemia virus-based lentiviral vectors.. Hum Gene Ther Methods 2012 Oct;23(5):309-23.
            doi: 10.1089/hgtb.2012.102pubmed: 23121195google scholar: lookup
          6. Carpenter S, Chen WC, Dorman KS. Rev variation during persistent lentivirus infection.. Viruses 2011 Jan;3(1):1-11.
            doi: 10.3390/v3010001pubmed: 21994723google scholar: lookup
          7. Mertz JA, Chadee AB, Byun H, Russell R, Dudley JP. Mapping of the functional boundaries and secondary structure of the mouse mammary tumor virus Rem-responsive element.. J Biol Chem 2009 Sep 18;284(38):25642-52.
            doi: 10.1074/jbc.M109.012476pubmed: 19632991google scholar: lookup
          8. Ihm Y, Sparks WO, Lee JH, Cao H, Carpenter S, Wang CZ, Ho KM, Dobbs D. Structural model of the Rev regulatory protein from equine infectious anemia virus.. PLoS One 2009;4(1):e4178.
            doi: 10.1371/journal.pone.0004178pubmed: 19137065google scholar: lookup
          9. Bogerd HP, Tallmadge RL, Oaks JL, Carpenter S, Cullen BR. Equine infectious anemia virus resists the antiretroviral activity of equine APOBEC3 proteins through a packaging-independent mechanism.. J Virol 2008 Dec;82(23):11889-901.
            doi: 10.1128/JVI.01537-08pubmed: 18818324google scholar: lookup
          10. Lee JH, Culver G, Carpenter S, Dobbs D. Analysis of the EIAV Rev-responsive element (RRE) reveals a conserved RNA motif required for high affinity Rev binding in both HIV-1 and EIAV.. PLoS One 2008 Jun 4;3(6):e2272.
            doi: 10.1371/journal.pone.0002272pubmed: 18523581google scholar: lookup
          11. Lee JH, Murphy SC, Belshan M, Sparks WO, Wannemuehler Y, Liu S, Hope TJ, Dobbs D, Carpenter S. Characterization of functional domains of equine infectious anemia virus Rev suggests a bipartite RNA-binding domain.. J Virol 2006 Apr;80(8):3844-52.
          12. Cochrane AW, McNally MT, Mouland AJ. The retrovirus RNA trafficking granule: from birth to maturity.. Retrovirology 2006 Mar 17;3:18.
            doi: 10.1186/1742-4690-3-18pubmed: 16545126google scholar: lookup
          13. Baccam P, Thompson RJ, Li Y, Sparks WO, Belshan M, Dorman KS, Wannemuehler Y, Oaks JL, Cornette JL, Carpenter S. Subpopulations of equine infectious anemia virus Rev coexist in vivo and differ in phenotype.. J Virol 2003 Nov;77(22):12122-31.
          14. Adams DJ, van der Weyden L, Mayeda A, Stamm S, Morris BJ, Rasko JE. ZNF265--a novel spliceosomal protein able to induce alternative splicing.. J Cell Biol 2001 Jul 9;154(1):25-32.
            doi: 10.1083/jcb.200010059pubmed: 11448987google scholar: lookup
          15. Guo W, Winistorfer SC, Stoltzfus CM. Selective inhibition of splicing at the avian sarcoma virus src 3' splice site by direct-repeat posttranscriptional cis elements.. J Virol 2000 Sep;74(18):8513-23.